HNE Formulary Change Effective 2/11/15
Posted on February 13, 2015
Effective 2/11/15, Viekira Pak will be HNE’s preferred product option for patients with genotype 1 hepatitis C virus. Harvoni will be excluded from the formulary, unless medically necessary. HNE will continue to require prior authorization for coverage for treatment for Hepatitis C for all patients. HNE will continue to cover Solvaldi and Olysio only when clinically appropriate or for those patients that have already begun treatment regimens.
Viekira is indicated for the treatment of adult patients with genotype 1, with sub type 1a or 1b chronic hepatitis C virus infection, including those with compensated cirrhosis. Health New England’s P&T Committee reviewed clinical trial information and concluded that Viekira is not only clinically equivalent to Harvoni but also more cost effective for patients with all genotype 1 hepatitis C virus. It is important to us that our members have access to a regimen that, in clinical trials, produced high cure rates with low rates of treatment failures, even in the most difficult to treat patients.
HNE has a responsibility to provide safe and effective treatments for our members while prudently managing total cost of care. Costs for specialty drugs continue to rise at double digit rates. We are pleased that we can now offer a lower cost alternative for our members who need treatment for Hepatitis C without compromising safety and a high cure rate.
Please click on the below attachment for a copy of medication request form.
